Allergy Therapeutics
plc
("Allergy
Therapeutics", "ATL" or the "Group")
Allergy Therapeutics
announces first patient treated in G308 Phase III trial to evaluate
long-term efficacy and safety of Grass MATA MPL in paediatric
patients
- Industry first long-term
subcutaneous allergen-specific
immunotherapy trial in paediatric subjects with grass induced
allergic rhinitis
27
November 2024 Allergy Therapeutics
(AIM: AGY), the fully integrated commercial biotechnology company
specialising in allergy immunotherapies, announces that the first
subject has been treated in the Phase III G308
trial to evaluate the long-term efficacy and safety of Grass MATA
MPL in paediatric subjects.
Grass MATA MPL incorporates
MicroCrystalline Tyrosine adsorbed allergoids and the adjuvant
Monophosphoryl-lipid A ("MPL"). This innovative technology only
requires patients to receive six doses prior to the grass allergy
season.
Treatment initiation in the G308
paediatric trial follows, as previously announced, the
completion of the Group's
pivotal Phase III G306 trial in adults and subsequent
submission of Marketing
Authorisation Application to the Paul Ehrlich Institut in Germany.
Grass MATA MPL has demonstrated a highly statistically significant
and clinically relevant reduction in the Combined Symptom &
Medication Score compared to placebo over the peak pollen season in
adults and the G308 trial is designed to evaluate long-term
efficacy and safety in a paediatric population.
Manuel Llobet, CEO of Allergy
Therapeutics, commented: "The start of the Phase III
G308 trial investigating the efficacy and safety of our Grass MATA
MPL in a paediatric population marks an exciting step in bringing
this innovative treatment to further patients affected by grass
allergies. Building on our successful adult trials, this study will
help us understand how our short-course immunotherapy can benefit
children affected by grass allergies, potentially transforming
their treatment journey."
- ENDS -
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
Geoff Nash /Giles Balleny/ Seamus
Fricker / Rory Sale
Nigel Birks - Life Science Specialist
Sales
Tamar Cranford Smith -
Sales
+44 (0)20 7220 0500
ICR
Healthcare
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the
potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. For more information, please see
www.allergytherapeutics.com.
About Grass MATA MPL
Grass MATA MPL is being developed as
a subcutaneous immunotherapy product for the treatment of allergic
rhinitis and/or rhinoconjunctivitis.
Grass MATA MPL contains an extract
of 13 grass pollens modified with glutaraldehyde to form allergoids
that reduces the reactivity with immunoglobulin E (IgE) antibodies
without a reduction in other important immunological properties,
such as T-cell reactivity. The allergoid is adsorbed to
microcrystalline tyrosine as a depot adjuvant system formulation.
Monophosphoryl lipid-A (MPL), is included as an adjuvant to
increase the immunogenic effect of the immunotherapy and to enhance
the switch from an allergen specific helper T-cell Type 2 (Th2) to
helper T-cell Type 1 (Th1) like immune response.